ATE206913T1 - Nasale und okulare anwendung von ketamin zur schmerzbeherrschung und entgiftung - Google Patents

Nasale und okulare anwendung von ketamin zur schmerzbeherrschung und entgiftung

Info

Publication number
ATE206913T1
ATE206913T1 AT95913499T AT95913499T ATE206913T1 AT E206913 T1 ATE206913 T1 AT E206913T1 AT 95913499 T AT95913499 T AT 95913499T AT 95913499 T AT95913499 T AT 95913499T AT E206913 T1 ATE206913 T1 AT E206913T1
Authority
AT
Austria
Prior art keywords
ketamine
nasal
occular
detoxification
pain control
Prior art date
Application number
AT95913499T
Other languages
English (en)
Inventor
Stuart L Weg
Original Assignee
Stuart L Weg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stuart L Weg filed Critical Stuart L Weg
Application granted granted Critical
Publication of ATE206913T1 publication Critical patent/ATE206913T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95913499T 1994-02-25 1995-02-24 Nasale und okulare anwendung von ketamin zur schmerzbeherrschung und entgiftung ATE206913T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/201,756 US5543434A (en) 1994-02-25 1994-02-25 Nasal administration of ketamine to manage pain
PCT/US1995/002418 WO1995022965A2 (en) 1994-02-25 1995-02-24 Nasal and ocular administration of ketamine to manage pain and for detoxification

Publications (1)

Publication Number Publication Date
ATE206913T1 true ATE206913T1 (de) 2001-11-15

Family

ID=22747152

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95913499T ATE206913T1 (de) 1994-02-25 1995-02-24 Nasale und okulare anwendung von ketamin zur schmerzbeherrschung und entgiftung

Country Status (11)

Country Link
US (1) US5543434A (de)
EP (1) EP0751766B1 (de)
JP (1) JP4729148B2 (de)
AT (1) ATE206913T1 (de)
CA (1) CA2184077C (de)
DE (1) DE69523295T2 (de)
DK (1) DK0751766T3 (de)
ES (1) ES2165910T3 (de)
MX (1) MX9603633A (de)
PT (1) PT751766E (de)
WO (1) WO1995022965A2 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679714A (en) * 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
CA2213567C (en) * 1995-02-24 2010-01-26 Stuart L. Weg Use of ketamine for facilitating detoxification and treatment of smoking addiction, and device therefor
US5496537A (en) * 1995-03-23 1996-03-05 Henry; Richard A. Propofol hydrofluorocarbon propellant formulations
WO1997007750A1 (en) * 1995-08-30 1997-03-06 Weg Stuart L Administration of ketamine to manage pain and to reduce drug dependency
US6197830B1 (en) * 1995-09-22 2001-03-06 Bruce M. Frome Method for achieving relief from sympathetically mediated pain
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US20040034107A1 (en) * 1999-02-11 2004-02-19 Mse Pharmazeutika Gmbh Ubiquinone Qn for the treatment of pain
EP1103256A1 (de) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
AU2001262992A1 (en) * 2000-05-10 2002-02-18 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
DE60133203T3 (de) * 2000-07-31 2012-02-23 Nycomed Danmark Aps Fentanyl Zusammensetzung für nasale Anwendung
EP1315533A4 (de) * 2000-08-15 2007-06-27 Univ Kentucky Res Found Programmierbare mehrdosenvorrichtung für intranasale medikamentenverabreichung
US20020106407A1 (en) * 2000-12-11 2002-08-08 Dennis Coleman Method and apparatus for treating breakthrough pain
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US6805853B2 (en) * 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
WO2002094218A2 (en) 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US20030138508A1 (en) * 2001-12-18 2003-07-24 Novack Gary D. Method for administering an analgesic
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
BR0210855A (pt) * 2001-07-06 2006-10-24 Penwest Pharmaceuticals Compan Método de fabricação de formulações de liberação prolongada
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US9820982B2 (en) 2001-07-06 2017-11-21 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
CA2459976A1 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
CA2506615A1 (en) * 2002-11-18 2004-06-03 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US20040213828A1 (en) * 2003-04-23 2004-10-28 Smith David J. Pain relief lollipop compositions and methods
US20040234699A1 (en) 2003-05-21 2004-11-25 Alexza Molecular Delivery Corporation Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
WO2005041963A1 (en) * 2003-10-21 2005-05-12 Arakis Ltd. The use of non-opiates for the potentation of opiates
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
EP2246086A3 (de) 2004-08-12 2012-11-21 Alexza Pharmaceuticals, Inc. Aerosolverabreichungsvorrichtung mit Schlag gezündete Heizeinheit
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
CN101466364A (zh) 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
US20080275030A1 (en) * 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
EP2121088B1 (de) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Erhitzungseinheit zur verwendung in einer arzneimittelabgabevorrichtung
WO2009103150A1 (en) * 2008-02-20 2009-08-27 Kevin David Smith Method for treating migraine headaches
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
AU2013305580A1 (en) * 2012-08-23 2015-04-09 Stuart L. Weg Anxiolytic composition, formulation and method of use
US20140275278A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
AU2014250756B2 (en) 2013-04-12 2019-03-07 Icahn School Of Medicine At Mount Sinai Method for treating post-traumatic stress disorder
HRP20211629T1 (hr) 2013-09-13 2022-02-04 National University Corporation Chiba University Primjena r-ketamina i njegove soli kao lijekova
EP3179993B1 (de) 2014-08-13 2021-01-20 Janssen Pharmaceutica NV Esketamine zur verwendung in einem verfahren zur behandlung von depression
CA2961208A1 (en) 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US10179136B2 (en) 2015-06-19 2019-01-15 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US20200297734A1 (en) 2015-06-19 2020-09-24 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US10166240B2 (en) 2015-06-19 2019-01-01 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US10391102B2 (en) 2015-06-19 2019-08-27 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
KR101964571B1 (ko) * 2015-06-19 2019-04-02 해로우 헬스 인코포레이티드 마취용 약학 조성물
US10555952B2 (en) 2015-06-19 2020-02-11 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
MX2020006650A (es) 2017-12-22 2020-11-06 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
US12214118B2 (en) 2018-02-02 2025-02-04 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
CN118453559A (zh) 2018-02-15 2024-08-09 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
CA3099293A1 (en) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Methods of treating substance abuse
US11154537B2 (en) 2018-08-10 2021-10-26 Eleusis Therapeutics Us, Inc. Method of treatment for ketamine infusion
WO2020178653A1 (en) 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
PT3976012T (pt) 2019-05-31 2024-04-09 Afyx Therapeutics As Administração intranasal de cetamina a doentes com cefaleia em salvas
US11160799B2 (en) * 2019-10-22 2021-11-02 Cessatech A/S Pediatric combination
PH12022551856A1 (en) 2020-01-22 2024-01-03 Seelos Therapeutics Inc Reducing side effects of nmda antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4334526A (en) * 1979-05-24 1982-06-15 Hamacher Edward N Method for administering a dissociative, unconscious type of anesthesia
US4671953A (en) * 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
US5132114A (en) * 1985-05-01 1992-07-21 University Of Utah Research Foundation Compositions and methods of manufacture of compressed powder medicaments
US5112804A (en) * 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration

Also Published As

Publication number Publication date
JP4729148B2 (ja) 2011-07-20
WO1995022965A3 (en) 1995-12-21
DE69523295T2 (de) 2002-07-11
PT751766E (pt) 2002-04-29
DK0751766T3 (da) 2002-02-11
US5543434A (en) 1996-08-06
CA2184077C (en) 2007-12-11
CA2184077A1 (en) 1995-08-31
EP0751766A1 (de) 1997-01-08
MX9603633A (es) 1998-01-31
DE69523295D1 (de) 2001-11-22
ES2165910T3 (es) 2002-04-01
WO1995022965A2 (en) 1995-08-31
JPH10500664A (ja) 1998-01-20
EP0751766B1 (de) 2001-10-17

Similar Documents

Publication Publication Date Title
DE69523295D1 (de) Nasale und okulare anwendung von ketamin zur schmerzbeherrschung und entgiftung
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
DE69600307D1 (de) Beatmungsgerät zur Behandlung von Ateminsuffizienzen
DE69528247D1 (de) Regulierung der Wasserbehandlungsmitteldosierung, auf Basis von Betriebssystemspannungen
DE122005000043I1 (de) Zusammensetzungen zur Erzielung von analgesie und zur Hemmung der Progression neuropatisher Schmerz erkrankungen
DE69521521D1 (de) Mono- oder polyfunktionelle konjugate von polylysine
NO980484D0 (no) Inhalator
DE69630947D1 (de) Mittel zur schmerzbehandlung
FI930656A7 (fi) Nasaalihoitoon tarkoitettu koostumus
DE69534908D1 (de) Verwendung von statin zur behandlung von hauterkrankungen
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
DE69526390D1 (de) Kugelförmige Aktivkohle zur Behandlung von Stoma-peripherer Entzündung
WO1997003188A3 (de) Verwendung von mp52 oder mp121 zur behandlung und prävention von erkrankungen des nervensystems
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
ATE297396T1 (de) Neue atropisomere von 2,3-disubstituierten-(5,6)- heteroarylkondensierten-pyrimidin-4-onen
DE69426848D1 (de) Gerät zur Behandlung von lichtempfindlichen Materialien
BG101338A (en) Dna encoding human papillomavirus type 6a
DE59806627D1 (de) Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
LV11940A (lv) Melatonina pielietojums personu arstesanai kuras cies no zalu atkaribas
DE69910425D1 (de) Neue therapeutische verwendung von nicergoline
FR2572286B1 (fr) Utilisation du 1-b-d-ribofuranosyl-1,2,4-triazole-3-carboxamide pour le traitement de maladies virales chez l'homme
DZ2012A1 (fr) Benzamides pour le traitement de dégénérescences neurologiques.
ATE307600T1 (de) Verwendung von mycobacterium vaccae zur therapie des chronischen müdigkeitssyndrom
DE69712057D1 (de) Neue vorrichtungen zur transdermalen verabreichung von trimegestone
ES2023620A4 (es) Salida de escape de purificador.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification